Treatment of familial male-limited precocious puberty (testotoxicosis) with anastrozole and bicalutamide in a boy with a novel mutation in the luteinizing hormone receptor

J Pediatr Endocrinol Metab. 2009 Dec;22(12):1163-7. doi: 10.1515/jpem.2009.22.12.1163.

Abstract

We report the use of anastrozole and bicalutamide in a 5 year-old boy with familial male-limited precocious puberty. Clinical response showed decreased advancement of skeletal maturation, secondary sexual characteristics and aggressiveness with no short-term side effects. The combination seems a better option until long-term data are available.

Publication types

  • Case Reports

MeSH terms

  • Anastrozole
  • Androgen Antagonists / administration & dosage
  • Androgen Antagonists / adverse effects
  • Anilides / administration & dosage*
  • Anilides / adverse effects
  • Aromatase Inhibitors / administration & dosage
  • Aromatase Inhibitors / adverse effects
  • Body Height
  • Body Weight
  • Child Development
  • Child, Preschool
  • Drug Therapy, Combination
  • Humans
  • Male
  • Nitriles / administration & dosage*
  • Nitriles / adverse effects
  • Point Mutation
  • Puberty, Precocious / drug therapy*
  • Puberty, Precocious / genetics*
  • Receptors, LH / genetics*
  • Tosyl Compounds / administration & dosage*
  • Tosyl Compounds / adverse effects
  • Triazoles / administration & dosage*
  • Triazoles / adverse effects

Substances

  • Androgen Antagonists
  • Anilides
  • Aromatase Inhibitors
  • Nitriles
  • Receptors, LH
  • Tosyl Compounds
  • Triazoles
  • Anastrozole
  • bicalutamide